PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022

Description: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

GlobalData expects HPV vaccine coverage rates in Australia to remain relatively high throughout the forecast period, driven by a successful school-based immunization program. The inclusion of males in the school immunization program from 2013 will drive the expansion of the HPV vaccines market over the forecast period. GlobalData expects that following approval Merck’s nine-valent vaccine V503 will be quickly adopted into the Australian school-based immunization program, and this will provide an additional boost to HPV vaccine sales in Australia.

Scope

- Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the Australia from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Australia Prophylactic Human Papillomavirus Vaccines disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the Australia

Contents:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccine Approval versus Routine Schedule Inclusion
9.4.3 Vaccines Included
9.4.4 Vaccine Launch Dates and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 About the Author(s)
9.6.1 Author(s)
9.6.2 Therapy Area Director
9.6.3 Global Head of Healthcare
9.7 About Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Histological Progression Towards Cervical Cancer
Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
Table 3: Marketed Vaccines for HPV, 2014
Table 4: Product Profile - Gardasil
Table 5: Phase III Efficacy Trials - Gardasil
Table 6: Safety Profile - Gardasil
Table 7: Gardasil SWOT Analysis, 2014
Table 8: Product Profile - Cervarix
Table 9: Phase III Efficacy Trials - Cervarix
Table 10: Safety Profile - Cervarix
Table 11: Cervarix SWOT Analysis, 2014
Table 12: Overall Unmet Needs - Current and Future Level of Attainment
Table 13: HPV Vaccines - Phase Pipeline, 2014
Table 14: Product Profile - V503
Table 15: V503 SWOT Analysis, 2013
Table 16: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014
Table 17: Sales Forecasts ($) for HPV Vaccines in Australia, 2012-2022
Table 18: Key Events Impacting Sales for HPV Vaccines in Australia, 2012-2022
Table 19: Australia HPV Vaccine Market - Drivers and Barriers, 2013
Table 20: Key Launch Dates
Table 21: Key Patent Expiries
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Historical and Projected HPV Vaccination Coverage (%) in Australia among 13-Year-Old Females, 2007-2022
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
Figure 3: Sales for HPV Vaccines in Australia by Vaccine Class, 2012-2022

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2881901/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2881901/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>Single User</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>Enterprisewide</td>
<td>USD 14985</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>Site License</td>
<td>USD 9990</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ___________________________  Last Name: ___________________________
First Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World